Depomed and Slán Medicinal Holdings Ltd Announce Strategic Asset Transactions
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
DepoMed Inc (DEPO) PT Lowered to $6 at RBC Capital Following 3Q Miss
November 8, 2017 8:13 AM ESTRBC Capital lowered its price target on DepoMed Inc (NASDAQ: DEPO) to $6.00 (from $8.00) while maintaining a Sector Perform rating. DEPO reported a 3Q top-line miss and another 2017E guidance step-down. Revenue came in at ~$95 million, below consensus of ~$99 million. Guidance was again lowered by $2030 million to... More
